The purpose of the Developmental Research Program is to promote the exploration of innovative ideas in translational research in lung cancer through the funding of pilot projects. Each year new pilot project applications are sought by the Developmental Research Committee, which is chaired by Dr. Bunn. Current committee members include Drs. Drabkin, Heasley, Franklin, Hirsch, Baron, and Keith. A request for application announcement is distributed to faculty at all consortium institutions of the University of Colorado Comprehensive Cancer Center (UCDHSC, CU-Boulder, Colorado State University, National Jewish Medical and Research Center, and The Children's Hospital). On average, 11 applications are received each year. The committee scores each application on its novelty, its likelihood of impacting the lung cancer burden through translational research, on its scientific merit, and on the qualifications of the investigators. The use of SPORE resources and the inclusion of collaborations with existing SPORE projects is also taken into consideration. Generally two applications are funded each year at a level of $50,000 each. Half of the support comes from SPORE funds and half comes from institutional funds. In some instances we have provided partial funding for worthy projects that could get started with more limited support. During the recent funding cycle we supported a total of 12 pilot projects. These projects and their outcomes are summarized in the following report. The success of our Developmental Research Program is demonstrated by the progression of a number of recent pilot projects into full SPORE projects. In this competitive renewal, Project 3 originated as a pilot project. As well, progress on the pilot projects of Dr. Heasley, of Dr. Meyer and of Drs. Solomon, Hansen and Duncan have been incorporated into the aims of Projects 2, 3 and 4, respectively. Pilot projects held by Drs. Nemenoff, Heasley, and Malkinson have led to current NCI R01s; the pilot project of Dr. Su has led to an NIH R21;and the pilot projects of Drs. Espinosa and Schiemann are incorporated into their NCI R01s. The research results from projects held by Drs. Franklin and Varella- Garcia were used to renew the NCI EDRN grant in 2005. As well, the Genetic Epidemiology Lung Cancer Consortium (GELCC) and the Lung Cancer Biomarkers &Chemoprevention Consortium (LCBCC) studies were also outcomes of SPORE pilot projects. Several other important lung cancer grants have been funded by other institutes and are described in this report.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-18
Application #
8376660
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
18
Fiscal Year
2012
Total Cost
$102,417
Indirect Cost
$30,148
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Oweida, Ayman; Lennon, Shelby; Calame, Dylan et al. (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology 6:e1356153
Blakely, Collin M; Watkins, Thomas B K; Wu, Wei et al. (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693-1704
Tan, Aik-Choon; Vyse, Simon; Huang, Paul H (2017) Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 22:72-84
Ziemke, Michael; Patil, Tejas; Nolan, Kyle et al. (2017) Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer 109:28-35
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Gautschi, Oliver; Milia, Julie; Filleron, Thomas et al. (2017) Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 35:1403-1410
Li, Howard Y; McSharry, Maria; Bullock, Bonnie et al. (2017) The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res 5:767-777
McCoach, C E; Blumenthal, G M; Zhang, L et al. (2017) Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 28:2707-2714
Vaishnavi, Aria; Schubert, Laura; Rix, Uwe et al. (2017) EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 77:3551-3563
Bruno, Tullia C; Ebner, Peggy J; Moore, Brandon L et al. (2017) Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res 5:898-907

Showing the most recent 10 out of 397 publications